Phillips-Medisize Grows Clinical Manufacturing Capabilities to Meet Demand
Phillips-Medisize has announced that it is expanding its current Global Innovation and Development (GID) site in Struer, Denmark, to include a dedicated manufacturing development and clinical build unit.
Phillips-Medisize has announced in a Jan. 8, 2020 press release that it is expanding its current Global Innovation and Development (GID) site in Struer, Denmark, to include a dedicated manufacturing development and clinical build unit.
The new unit, designed to support late stage development of medium- and high-volume products and processes, is scheduled to be open in the second quarter of 2020 and will be equipped to serve clients with agile set up for cleanroom assembly and molding. The cleanroom space will be created by repurposing approximately 500 m2of floor space from the existing building.
“This expansion accelerates the manufacture of innovative, compliant, and best-in-class products while reducing time to market and lowering launch risk for drug delivery device customers,” said John Horgan, vice-president, Global Sales and Marketing of Phillips-Medisize, in the press release. “Furthermore, it strengthens our client focus in Scandinavia by complementing the activities of our existing GID in Struer and our newest GID in Copenhagen.”
Source: Phillips-Medisize
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
